Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

CEO

Ron Cohen

Karyawan

111

Negara

ISIN

US00484M6012

WKN

000A2QLBW

Pencatatan

0 Comments

Bagikan pendapatmu

FAQ

Berapa harga saham Acorda Therapeutics hari ini?▼

Harga saat ini dari ACOR adalah $0.66 USD — turun sebesar -24.86% dalam 24 jam terakhir. Pantau kinerja harga saham Acorda Therapeutics lebih dekat di grafik.

Apa simbol saham Acorda Therapeutics?▼

Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa , saham Acorda Therapeutics diperdagangkan dengan simbol ACOR.

Berapa pendapatan Acorda Therapeutics tahun lalu?▼

Pendapatan Acorda Therapeutics tahun lalu berjumlah 117.63M USD.

Berapa pendapatan bersih Acorda Therapeutics tahun lalu?▼

Pendapatan bersih ACOR untuk tahun lalu adalah -252.85M USD.

Berapa jumlah karyawan Acorda Therapeutics?▼

Per April 01, 2026, perusahaan memiliki 111 karyawan.

Acorda Therapeutics berada di sektor apa?▼

Acorda Therapeutics beroperasi di sektor Manufacturing.

Kapan Acorda Therapeutics menyelesaikan split saham?▼

Pemecahan saham terakhir Acorda Therapeutics terjadi pada Juni 05, 2023 dengan rasio 1:20.

Di mana kantor pusat Acorda Therapeutics?▼

Kantor pusat Acorda Therapeutics berlokasi di Ardsley, US.